GLP-1 users are not reaching for diet food. They are reaching for better food. Here is what that means for the products you are building right now.
GLP-1 is changing what people want to eat
Here is a number I want to start with: premium chocolate sales rose 17% among GLP-1 users in 2025.
Sit with that for a moment, because it cuts directly against the story most of the food and drink industry is telling itself about this consumer. The dominant assumption is straightforward. GLP-1 users eat less, therefore they spend less, therefore your volumes go down. That instinct is not entirely wrong. But it is only half the picture. And the brands that have stopped at that conclusion are already ceding ground to the ones who kept reading.
If you have a product on shelf or in development and you have not yet thought seriously about what GLP-1 drugs mean for your formulation, this is a good moment to start. And if you want to think through the implications for your specific product, a free discovery call is a practical place to begin that conversation.
What these drugs actually do
GLP-1 stands for glucagon-like peptide 1. The brand names will be familiar: Ozempic, Wegovy, Mounjaro. Originally developed for managing type 2 diabetes, they are now used widely for weight management across the UK.
The way they work is worth understanding properly. They slow gastric emptying, reduce appetite, and dampen what researchers are calling food noise: that persistent mental chatter around eating, the cravings, the impulse decisions, the feeling of never quite being satisfied.
In the UK, GLP-1 prescriptions have tripled in two years. These users now represent 6% of British households. And with the Wegovy oral pill recently approved in the UK, the cost and accessibility barrier is dropping significantly. No more injections. No fridge storage required. This is not a niche health trend moving slowly through a narrow population.
The commercial story most brands are only reading halfway
A survey of over 11,500 British households found that GLP-1 users collectively reduced their annual grocery spend by £780 million. Within that, 72% cut back on crisps and 75% cut back on chocolate.
Those are the numbers that tend to dominate the industry conversation. And they are worth taking seriously.
But they are not the whole story. The same research found that premium chocolate sales rose 17% among GLP-1 users in 2025. That is not an anomaly to be explained away. That is the signal that reframes everything else in the data.
When you can only eat a little, it has to be worth it
This is the finding that matters most for anyone working in product development right now. GLP-1 drugs suppress the wanting, the impulse, the craving. They do not suppress the liking. The sensory pleasure of eating, once food is actually in the mouth, remains largely intact.
GLP-1 users are not eating less because food stopped bringing them satisfaction. They are eating less because the drive to eat has been turned down. So when they do choose something, it is a deliberate, considered decision. They want whatever they have chosen to genuinely deliver.
That is why premium chocolate is growing. Not because this group developed expensive tastes overnight. Because if you can only eat a small amount that day, it needs to actually be worth it.
Selective, not restrictive
This is a distinction worth being precise about. GLP-1 users are not looking for diet food. They are not reaching for low-fat, reduced-calorie, or reduced-sugar products out of obligation. They are gravitating towards yogurt, kefir, soups, fruit, porridge, and vegetables, not because those choices feel virtuous, but because they sit more comfortably on a stomach that now fills up quickly.
What they are actively seeking is real nutrients: protein, fibre, vitamins, real ingredients, and a flavour experience that feels genuinely satisfying at the smaller portion they are going to eat.
They are also reading your label. Research from Circana shows that 59% of GLP-1 users in Europe are now paying closer attention to ingredient lists, and that habit persists even after they stop taking the medication. The question this consumer is asking, consciously and deliberately, is whether your product actually justifies the space it is about to take up.
The taste picture is more complicated than it first appears
One strand of research found that roughly 85% of GLP-1 users experienced weakened perception across all five basic tastes. The popular narrative from this is that these drugs dull the senses.
MMR Research found almost the opposite. More than half of GLP-1 users in their study reported more intense sweetness. 37% experienced higher saltiness. 34% experienced heightened sourness. Two bodies of research, pointing in different directions. What that tells us is that the science is still developing, and that anyone claiming a definitive answer right now is probably oversimplifying.
What does appear consistently across multiple studies is Ozempic mouth: a side effect involving metallic taste or dry mouth that makes anything very sweet, very salty, or alcohol-forward significantly less pleasant. There is also a consistent finding around bitterness sensitivity. GLP-1 users tend to be more sensitive to bitter aftertastes in sweetness, meaning that a reformulation strategy built around swapping sugar for sweeteners is unlikely to land as well as you hope with this group.
What the brands reading this right are already doing
Marks and Spencer is a useful point of reference here. They launched a nutrient-dense range developed with chefs and nutritionists, with positioning that speaks directly to what GLP-1 users are looking for: packed with more flavours, fibre, vitamins and minerals into every bite, perfectly portioned to deliver a high level of nutrients per calorie.
That brief works because it actually understands what this consumer is asking. Smaller portions. High nutrient density. Real ingredients. And a flavour experience that delivers at that reduced scale.
If you are not sure whether your current product could make the same kind of claim confidently, that is worth sitting with. It is also exactly the kind of question worth working through before spending months reformulating in the wrong direction. A free discovery call is a good place to start that thinking.
Three questions worth asking about your current product
If you are building or developing a product right now, these are the three places I would start.
Does the flavour actually deliver at a smaller portion size? Flavour intensity in a reduced format is harder to get right than most founders expect. The portion changes everything about how the flavour lands, and this is where products often fall short without anyone identifying why.
Does your ingredient list hold up to close reading? Not just from a health credentials perspective, but from the standpoint of a consumer who is now reading every line carefully and asking whether this product feels considered and trustworthy.
Is the texture comfortable, or does it feel heavy and demanding on a stomach that is no longer accustomed to large volumes?
Those three questions are a solid starting point for understanding how ready your product is for this shift. And if you want to work through any of them properly with someone who can look at your specific formulation, you can book a discovery call here.
The window for getting ahead of this is now
GLP-1 drugs are moving from early adopter to mainstream faster than most of the food and drink industry is tracking. The oral pill approval in the UK changes the adoption curve meaningfully. Within 12 to 18 months, this consumer group will be a significant part of your customer base, whether or not you have designed for them.
The brands asking the right product development questions now, around flavour density, ingredient quality, portion design, and label transparency, already have a real advantage. Not because they are chasing a trend, but because they understand that the consumer relationship with food is changing, and they are making sure their products are ready for it.
If that is a conversation you want to have about a specific product you are working on, book a free discovery call with me here. This is a topic I will keep returning to as the research develops, so make sure you are subscribed so you do not miss the next piece.
